Develops antibody therapeutics by leveraging deep learning and adaptive immunity to identify and replicate antibodies from resilient individuals, such as long-term cancer survivors. This approach targets hard-to-treat diseases, providing a potential solution for conditions like Parkinson’s disease.

Alector uses a genetics‑first platform to identify protein pathways linked to neurodegeneration and develops CNS‑penetrant therapeutics—including monoclonal antibodies, engineered proteins, and gene‑delivery vectors—that clear toxic aggregates or modulate microglial activity. Its programs incorporate biomarker‑guided patient stratification and adaptive trial designs to accelerate development of disease‑modifying treatments for Alzheimer’s disease, frontotemporal dementia, and ALS.

The startup develops targeted protein degradation therapeutics that utilize novel mechanisms to modulate the degradation of disease-related proteins. This approach aims to enhance therapeutic efficacy for a range of diseases by precisely regulating protein abundance linked to disease progression.

AstronauTx is developing targeted therapeutics to restore the functionality of astrocytes, which are critical for maintaining brain health. This approach aims to correct disrupted brain physiology associated with neurodegenerative diseases, potentially improving patient outcomes.

Cerevance utilizes its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify novel therapeutic targets for neurological diseases, including Parkinson's and Alzheimer's. The company develops cell type-specific therapies aimed at addressing the unmet medical needs associated with neurodegenerative and psychiatric disorders.

This platform provides a digital space for users to upload photos, videos, and audio files to create 3D memorials for loved ones. By creating an immersive experience, the platform helps individuals preserve memories and cope with grief.

E INC enhances the automotive purchasing process by providing a digital platform that streamlines wholesale and retail transactions through advanced technology and data analytics. This approach addresses inefficiencies in the automotive ecosystem, enabling faster and more flexible business operations for dealers and consumers.

Leal Therapeutics develops precision neuro-metabolic therapies for central nervous system disorders. The company's pipeline includes an ASO targeting lipid biology for ALS and an oral small molecule targeting glutamate biology for schizophrenia. These programs aim to address high-need CNS indications through novel therapeutic modalities.

LoQus23 targets DNA damage repair pathways to treat Huntington's disease, focusing on mitigating neurodegeneration caused by DNA instability. The company's approach aims to enhance cellular repair mechanisms, potentially slowing disease progression and improving patient outcomes.

NRG Therapeutics is a drug discovery company developing oral small molecule inhibitors targeting the mitochondrial permeability transition pore (mPTP) to restore mitochondrial function. The company aims to slow or halt the progression of neurodegenerative diseases such as Parkinson’s and Amyotrophic Lateral Sclerosis (ALS).

Provides an API-driven authorization service that enables developers to implement role-based (RBAC), relationship-based (ReBAC), and attribute-based (ABAC) access control without overhauling existing application architectures. By generating SQL filters and authorizing locally against existing databases, it reduces integration time, eliminates syncing issues, and supports high-performance, scalable permission management across cloud, hybrid, and on-prem environments.

The startup develops precision therapeutics and diagnostic tools targeting genetically validated alterations in amyotrophic lateral sclerosis and other neurodegenerative diseases. Its proprietary platforms enable the design of drugs that can halt disease progression and improve patient outcomes through direct intervention on genetic factors.

Ribometrix develops small molecule drugs that target RNA biology to prevent the production of disease-causing proteins, addressing challenges in treating complex diseases such as cancer and autoimmune disorders. By binding directly to mRNAs or mRNA-binding proteins, Ribometrix's platform offers a novel approach to drug discovery that aims to manipulate key regulatory mechanisms in human health.

Ro operates a telehealth platform that provides online clinics for weight loss, sexual health, hair restoration, and fertility management using clinically proven treatments and prescription medications. The service eliminates the need for insurance and offers free, discreet shipping, making healthcare accessible and convenient for over 2 million members.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

Sudo Bio provides a cloud‑based platform that automates the integration, cleaning, normalization, and statistical analysis of multi‑omics datasets, allowing researchers and clinicians to extract actionable insights without deep bioinformatics expertise.

The startup offers an AI-driven platform that connects businesses with suitable partners throughout their innovation journey. By leveraging machine learning algorithms, it enhances strategic collaboration, enabling companies to identify and engage with startups that align with their specific needs.

Therini Bio develops fibrin-targeting immunotherapies to address chronic neuroinflammation and neuronal damage caused by vascular dysfunction in diseases such as Alzheimer’s and Diabetic Macular Edema. Their clinical-stage pipeline focuses on selectively eliminating toxic fibrin deposits that trigger inflammatory cascades, aiming to improve outcomes for patients with severe neurological and retinal conditions.

Trim utilizes transaction analysis to identify and eliminate unwanted subscriptions, helping users save an average of $213 annually. The platform enhances financial health for over 3 million members by providing insights into recurring expenses and facilitating better budget management.

Violet Therapeutics utilizes first-in-class platforms to identify and map the cellular connectome, enabling detailed insights into cellular interactions and functions. This technology addresses the challenge of understanding complex cellular networks, which is crucial for advancing therapeutic development in various diseases.